Asporin, A Candidate Protein for Treatment of Disc Degenerative Disease
Tian Wei,Zheng Shan,Jiang Xiao-zhou,Wu Cheng-ai,Wang Na,Zhao Dan-hui
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20110246
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:The human spine carries the weight of the trunk, upper extremities, and head, and provides an extensive range of motion. Due to heavy use and lack of vasculature, the intervertebral discs degenerate much more rapidly than other structures of the human body.1 Intervertebral disc degeneration is mostly age-related,2 and spinal disorders associated with disc degeneration have a significant impact on society.3,4 Indeed, low back pain affects nearly three-quarters of the population sometime in their life.3 Surgical strategies for treatment of disc degenerative disease (DDD) include removal of pathological discs and fusion of intervertebral bodies or facet joints with or without instrumentation. Spinal fusion enhances the stability of the spine and decreases the formation of pseudo-unions; however, this procedure is also associated with breakage or loosening of the instruments and acceleration of adjacent segment degeneration.4,5 As an alternative to disc fusion, artificial disc (AD) replacement using a disc prosthesis results in a greater degree of segment motion.6–8 Complications of AD include periprosthetic ossification, neurological deficit, prosthetic looseness or breakage, and even cervical kyphosis.8 Since conservative methods for treatment of DDD eventually fail and surgical interventions have significant drawbacks and complications, non-operative (biological) strategies such as growth factor injection, stem cell transplantation, and gene therapy have begun to receive more attention.4, 9-11 Animal trials and human clinical trials of gene therapy for rheumatoid arthritis, bone and soft tissue tumors, and osteogenesis imperfecta have been performed.9,11 However, none of these trials involved repair of cartilage-like tissue such as articular cartilage, meniscus, ligaments and tendons, or intervertebral discs.11 Twin studies suggest that genetics play an important role in lumbar disc degeneration.12–15 Research has shown several factors to be involved in degeneration of intervertebral discs, including Secreted Protein, Acidic, and Rich in Cysteine (SPARC), Insulin-like Growth Factor-1 Receptor (IGF1R), Trp3 allele in COL9A3, and asporin (ASPN).16–19 This review will focus on ASPN. STRUCTURE AND EXPRESSION OF ASPN ASPN is a member of the small leucine-rich repeat proteoglycan (SLRP) family. SLRP is a subgroup of the leucine-rich repeat (LRR) superfamily of extracellular matrix proteins.20,21 Members of an SLRP subgroup have similar-sized core proteins of 6 to 10 tandemly repeated LRRs.20 The SLRP family members can be classified into three subgroups, based on the similarities of amino sequence, spacing of cysteine residues in the amino terminus, and gene structure.20 Class I SLRP members, decorin or dermatan, have 10 LRRs in the core protein and carry one or two chondroitin or dermatan sulfate chains in the amino terminus, respectively.20, 21 ASPN differs from other class I SLRP members in that it has an aspartic acid (D) repeat region at its amino terminus rather than sequences for glycosaminoglycan attachment.20,22 Human ASPN is about 50% identical and 70% similar to decorin and biglycan. The human ASPN gene spans 26 kb on chromosome 9q31.1-32, and includes eight exons.21,22 In mouse embryos, ASPN mRNA is expressed in the perichondrium/periosteum of the maxilla, mandible, vertebrae, and long bones, but not in the epiphysial cartilage.20,23 In humans, ASPN mRNA is expressed in many tissues, with higher levels in osteoarthritic articular cartilage, aorta, and uterus.21 In teeth, ASPN is expressed in the periodontal ligament (PDL) and in the dental follicle (the progenitor of the PDL) and acts as a negative regulator of mineralization and cytodifferentiation of PDL cells.24 Tomoeda et al found that the function of ASPN was to inhibit bone morphogenic protein-2 (BMP-2) induced differentiation of PDL cells. Using an in vitro model of chondrogenesis, ASPN expression was found to decrease during cartilage differentiation.22,25 These findings together suggest that ASPN is associated with bone and cartilage cell differentiation. AMINO ACID REPEAT POLYMORPHISM OF ASPN The ASPN protein contains a repeat of 9 to 20 aspartic acid (D) residues at the N-terminus.21 Kizawa et al25 reported that the D repeats of ASPN are associated with osteoarthritis. Lida et al found a total of 19 different ASPN alleles, of which the D14 allele is more common in individuals with knee/hip osteoarthritis and its frequency increases with the severity of the disease.26 In addition, the product of D14 allele inhibits TGF-β mediated gene expression of aggrecan (AGC1) and Type II collagen (COL2A1) better than other alleles. COL2A1 and AGC1 are the major macromolecular components of normal discs.27 The degradation of AGC1 and denaturation of COL2A1 results in dehydration and degeneration of intervertebral discs leading to rupture of the discs.27 A study of UK Caucasians (Mustafa et al) found that the ASPN D14 allele was more common among osteoarthritis patients, and was highly expressed in men who had undergone hip replacement.28 An association between ASPN polymorphisms and osteoarthritis has also been shown in Han Chinese and Japanese populations.29 In contrast, no association between ASPN polymorphisms and hand or knee osteoarthritis was found in U.S. Caucasians (Atif et al).30 A meta-analysis of studies of Asian populations affirmed the association between the ASPN D-repeat polymorphisms and osteoarthritis.31 Since osteoarthritis and DDD are similar joint disorders and since hyaline cartilage occurs in both the disc endplate and the articular cartilage, ASPN polymorphisms were studied as a possible candidate for DDD susceptibility. Song32 and his colleagues found that in a large cohort of Chinese and Japanese, individuals harboring the ASPN D14 allele had a higher risk of lumbar disc degeneration. Furthermore, ASPN mRNA expression measured by RT-PCR showed an upregulation in more degenerate discs, and a trend for a reduced expression of COL2A1 in the annulus fibrosis and of AGC1 in the nucleus pulposus and cartilage endplate.32 REGULATORY EFFECT OF ASPN ASPN is involved in cartilage extracellular matrix (ECM) formation as a negative regulator of the TGF-β/Smad pathway.22,23,25,33 Ligand binding to the TGF-β transmembrane receptor initiates downstream signaling through the Smad pathway to stimulate or repress gene transcription.23 All TGF-β isoforms (β1, β2, and β3), similarly induced ASPN expression in all chondrocytic cells examined. TGF-β1, however, is most abundant in articular cartilage and normal human articular chondrocyte (NHAC) cells, so the temporal profile of ASPN expression in response to TGF-β1 was examined. ASPN expression was induced within 3 to 6 hours of TGF-β1 (10 ng/ml) stimulation and increased with time up to 24 hours in NHAC, HCS-2/8, and OUMS-27 cells. In unstimulated NHAC cells, no ASPN expression was observed over 24 hours. Thus, TGF-β1 positively regulates ASPN expression in cartilage. Inhibition of TGF-β1 completely suppresses TGF-β1 induced ASPN expression. Knockdown of endogenous Smad3 after TGF-β1 stimulation repressed TGF-β1-induced ASPN expression at both the mRNA and protein levels. Smad3 overexpression increased TGF-β1 induced ASPN expression at both the mRNA and protein levels. Taken together, these results indicate that Smad3 dominantly mediates TGF-β1 induced ASPN expression. Pretreatment with CHX or actinomycin-D 0.5 hour prior to addition of TGF-β1 effectively blocked ASPN induction, suggesting that the TGF-β/Smad signal regulates ASPN expression indirectly through de novo protein synthesis.23 ASPN binds directly to TGF-β1 and inhibits Smad signaling in chondrocytes.25 Thus, ASPN and TGF-β/Smad form a functional feedback loop within cartilage ECM during de novo protein synthesis. In differentiating ATDC5 cells, TGF-β rapidly induces transcription of the marker genes AGC1 and COL2A1. In cells overexpressing ASPN, expression of AGC1 and COL2A1 genes was suppressed when treated with TGF-β.25 Knockdown of ASPN significantly increased the mRNA expression of type II collagen and aggrecan as well as TGF-β1.33 Recent research of Kou et al34 showed that amino acids 159-205 of the ASPN protein mediate its interaction with TGF-β1 and that ASPN has the ability to bind type II collagen. In the presence of heparin/heparan sulfate, ASPN inhibits the interaction between TGF-β and TβRII, and effectively represses TGF-β1 induced cartilage matrix gene expression in vitro.34 Thus, the identified signaling pathway of ASPN involves positive induction by TGF-β1 and the suppression of AGC1 and COL2A1, in addition to a feedback mechanism binding to TGF-β1. ASPN PROTEIN IN DEGENERATE DISCS In degenerate discs, RT-PCR showed upregulated ASPN expression and a trend toward reduced expression of COL2A1 and AGC1.32 Immunostaining with an antibody specific for ASPN showed a stronger signal in all degenerative discs analyzed compared to "normal" non-degenerative tissues. In non-degenerative intervertebral discs, TGF-β1 can be detected in the cartilage end plate, nucleus pulposus, and annulus fibrosus, regions where ASPN is also localized.32 Studies of disc specimens in vivo showed ASPN mRNA expression levels were significantly greater in more degenerate discs (Thompson grade IV) compared to expression levels in healthier discs (Thompson grade I, II, and III).16 Our research of human disc cell cultures showed that ASPN protein levels increased with severity of disc degeneration, and negatively regulated disc ECM synthesis (data not shown). ASPN CANDIDATE STUDIES The involvement of ASPN with DDD has been clearly shown. Furthermore, a functional feedback loop involving ASPN which was identified in degenerative articular cartilage may also exist in intervertebral discs. Thus, new, noninvasive strategies for treatment of DDD that target ASPN should be considered. It is possible that downregulation of ASPN expression in certain tissues would lead to an increase in TGF-β induced type II collagen and aggrecan synthesis. As a result, the degenerative process could be slowed, and normal disc structure could be sustained for greater lengths of time. However, bone and cartilage remodeling is a normal process during fracture healing; thus such a therapy may be contraindicated in patients with high risk of bone fracture. CONCLUSIONS The ASPN protein plays an important role in the process of the intervertebral disc degenerative disease. The ASPN functional feedback loop within intervertebral discs is not entirely understood, but further research into therapies targeting ASPN expression levels could lead to less invasive treatment options for DDD.